

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>MPM BioVentures 2014, L.P.</u> (Last) (First) (Middle) C/O MPM CAPITAL 450 KENDALL STREET (Street) CAMBRIDGE MA 02142 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>iTeos Therapeutics, Inc. [ITOS]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 04/07/2021	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	04/07/2021		s ⁽¹⁾		3,164 ⁽²⁾	D	\$32.07 ⁽³⁾	3,703,499	I	See Footnote ⁽⁴⁾
Common Stock	04/07/2021		s ⁽¹⁾		1,842 ⁽⁵⁾	D	\$32.84 ⁽⁶⁾	3,701,657	I	See Footnote ⁽⁷⁾
Common Stock	04/07/2021		s ⁽¹⁾		777 ⁽⁸⁾	D	\$33.84 ⁽⁹⁾	3,700,880	I	See Footnote ⁽¹⁰⁾
Common Stock	04/07/2021		j ⁽¹¹⁾		15,670 ⁽¹²⁾	D	\$0.00	3,685,210	I	See Footnote ⁽¹³⁾
Common Stock	04/08/2021		s ⁽¹⁾		19,057 ⁽¹⁴⁾	D	\$30.51 ⁽¹⁵⁾	3,666,153	I	See Footnote ⁽¹⁶⁾
Common Stock	04/08/2021		s ⁽¹⁾		247 ⁽¹⁷⁾	D	\$31.01 ⁽¹⁸⁾	3,655,906	I	See Footnote ⁽¹⁹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
						Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person*
MPM BioVentures 2014, L.P.
 (Last) (First) (Middle)
 C/O MPM CAPITAL
 450 KENDALL STREET
 (Street)
 CAMBRIDGE MA 02142
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
EVNIN LUKE
 (Last) (First) (Middle)
 C/O MPM CAPITAL

450 KENDALL STREET

(Street)

CAMBRIDGE MA 02142

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[Foley Todd](#)

(Last)

(First)

(Middle)

C/O MPM CAPITAL
450 KENDALL STREET

(Street)

CAMBRIDGE MA 02142

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[MPM BioVentures 2014 \(B\), L.P.](#)

(Last)

(First)

(Middle)

C/O MPM CAPITAL
450 KENDALL STREET

(Street)

CAMBRIDGE MA 02142

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[MPM Asset Management Investors BV2014 LLC](#)

(Last)

(First)

(Middle)

C/O MPM CAPITAL
450 KENDALL STREET

(Street)

CAMBRIDGE MA 02142

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[MPM BioVentures 2014 LLC](#)

(Last)

(First)

(Middle)

C/O MPM CAPITAL
450 KENDALL STREET

(Street)

CAMBRIDGE MA 02142

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[MPM BioVentures 2014 GP LLC](#)

(Last)

(First)

(Middle)

C/O MPM CAPITAL
450 KENDALL STREET

(Street)

CAMBRIDGE MA 02142

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[MPM BIOVENTURES 2018 \(B\), L.P.](#)

(Last) (First) (Middle)

C/O MPM CAPITAL
450 KENDALL STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

1. Name and Address of Reporting Person *

MPM ASSET MANAGEMENT INVESTORS
BV2018 LLC

(Last) (First) (Middle)

C/O MPM CAPITAL
450 KENDALL STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

Explanation of Responses:

1. Transaction effected pursuant to a plan established pursuant to Rule 10b5-1.
2. The shares were sold as follows: 1,885 by MPM BioVentures 2014, L.P. ("BV 2014"), 65 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 1,191 by MPM BioVentures 2018, L.P. ("BV 2018") and 23 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evinin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$31.50 to \$32.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The shares are held as follows: 2,082,002 by BV 2014, 138,985 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 71,662 by AM BV2014, 1,314,948 by BV 2018, 69,951 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)") and 25,951 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
5. The shares were sold as follows: 1,097 by BV 2014, 38 by AM BV2014, 693 by BV 2018 and 14 by AM BV2018.
6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$32.50 to \$33.265 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
7. The shares are held as follows: 2,080,905 by BV 2014, 138,985 by BV 2014(B), 71,624 by AM BV2014, 1,314,255 by BV 2018, 69,951 by BV 2018(B) and 25,937 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
8. The shares were sold as follows: 463 by BV 2014, 16 by AM BV2014, 292 by BV 2018 and 6 by AM BV2018.
9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$33.50 to \$34.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
10. The shares are held as follows: 2,080,442 by BV 2014, 138,985 by BV 2014(B), 71,608 by AM BV2014, 1,313,963 by BV 2018, 69,951 by BV 2018(B) and 25,931 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
11. Represents a pro rata in-kind distribution from BV 2014(B) and BV 2018(B) to its respective limited partners for no consideration.
12. The shares were distributed as follows: 10,424 by BV 2014(B) and 5,246 by AM BV 2018(B).
13. The shares are held as follows: 2,080,442 by BV 2014, 128,561 by BV 2014(B), 71,608 by AM BV2014, 1,313,963 by BV 2018, 64,705 by BV 2018(B) and 25,931 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
14. The shares were sold as follows: 11,354 by BV 2014, 391 by AM BV2014, 7,171 by BV 2018 and 141 by AM BV2018.
15. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$29.95 to \$30.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
16. The shares are held as follows: 2,069,088 by BV 2014, 128,561 by BV 2014(B), 71,217 by AM BV2014, 1,306,792 by BV 2018, 64,705 by BV 2018(B) and 25,790 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
17. The shares were sold as follows: 147 by BV 2014, 5 by AM BV2014, 93 by BV 2018 and 2 by AM BV2018.
18. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$30.945 to \$31.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
19. The shares are held as follows: 2,068,941 by BV 2014, 128,561 by BV 2014(B), 71,212 by AM BV2014, 1,306,699 by BV 2018, 64,705 by BV 2018(B) and 25,788 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Remarks:

See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing.

/s/ Ansbert Gadicke, managing
director of MPM BioVentures
2014 LLC, the managing
member of MPM BioVentures 04/09/2021
2014 GP LLC, the general
partner of MPM BioVentures
2014, L.P.

/s/ Luke Evinin 04/09/2021

/s/ Todd Foley 04/09/2021

/s/ Ansbert Gadicke, managing
director of MPM BioVentures
2014 LLC, the managing
member of MPM BioVentures 04/09/2021
2014 GP LLC, the general
partner of MPM BioVentures
2014 (B), L.P.

/s/ Ansbert Gadicke, managing 04/09/2021
director of MPM BioVentures

2014 LLC, the manager of
MPM Asset Management
Investors BV2014 LLC

/s/ Ansbert Gadicke, managing
director of MPM BioVentures 04/09/2021
2014 LLC

/s/ Ansbert Gadicke, managing
director of MPM BioVentures
2014 LLC, the managing 04/09/2021
member of MPM BioVentures
2014 GP LLC

/s/ Ansbert Gadicke, managing
director of MPM BioVentures
2018 LLC, the managing 04/09/2021
member of MPM BioVentures
2018 GP LLC, the general
partner of MPM BioVentures
2018 (B), L.P.

/s/ Ansbert Gadicke, managing
director of MPM BioVentures
2018 LLC, the manager of 04/09/2021
MPM Asset Management
Investors BV2018 LLC

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.